Delhi HC rejects F Hoffmann-La interim injunction plea against Natco Pharma
This story was originally published at 21:19 IST on 24 March 2025
Register to read our real-time news.Informist, Monday, Mar. 24, 2025
NEW DELHI – The Delhi High Court on Monday rejected a plea by F. Hoffmann-La Roche AG and others seeking interim injunction against Natco Pharma Ltd. to restrain infringement of the patent titled "compounds for treating spinal muscular atrophy". "...it is held that the defendant, i.e. Natco Pharma Ltd., has prima facie raised a credible challenge to the validity of the suit patent," said the court.
Thus, the high court is not inclined to grant any injunction in favour of petitioners and against the defendant, said Justice Mini Pushkarna. Further, balance of convenience is also against the plaintiffs and is in favour of the defendant, she added.
The patent, which is a "species patent" for the product "Risdiplam", relates to compounds which are survival motor neuron used in the treatment of spinal muscular atrophy. The patent is registered in the name of the petitioners. Risdiplam is the active pharmaceutical ingredient in the plaintiffs' commercial product, which is marketed in various countries worldwide, including, India, under the brand name Evrysdi(risdiplam). Risdiplam is an oral prescription medicine indicated for the treatment of spinal muscular atrophy in patients two months of age or older.
The plaintiffs had come across the listing of Risdiplam on Natco Pharma's website under the "APIs under development" section. Further investigation revealed that the defendant was preparing for commercial production of Risdiplam API, said the plaintiffs. Moreover, the defendant was found to have filed a patent application in September, 2022 under the title, "Improved Process for the Preparation of Risdiplam and its Intermediates" for manufacturing of Risdiplam, said the plaintiffs. Thus, the present suit has been filed by the plaintiffs alleging infringement by the defendant of their rights in their patent.
On Monday, shares of Natco Pharma closed flat at INR 829.90 on the National Stock Exchange. End
Reported by Surya Tripathi
Edited by Deepshikha Bhardwaj
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
